Celldex Therapeutics (CLDX) financial statements
Celldex Therapeutics reported revenue of $2M in fiscal 2025, down 15.2% a year over 9 years.
Net income was -$259M and the operating margin -18599.8%, against -1958.7% in 2016.
Free cash flow was -$214M.
The diluted share count rose 881% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Celldex Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7M | $13M | $10M | $4M | $7M | $5M | $2M | $7M | $7M | $2M |
| Cost of revenue | $2M | $700,000 | $700,000 | $100,000 | $200,000 | $100,000 | $100,000 | $300,000 | $200,000 | $200,000 |
| Research and development | $103M | $96M | $66M | $43M | $43M | $53M | $82M | $118M | $164M | $245M |
| Selling, general and admin | $36M | $25M | $19M | $15M | $14M | $20M | $27M | $31M | $39M | $44M |
| Operating income | -$133M | -$122M | -$156M | -$55M | -$63M | -$71M | -$115M | -$155M | -$195M | -$287M |
| Pre-tax income | -$129M | -$117M | -$152M | -$51M | -$61M | -$71M | -$112M | -$141M | -$158M | -$259M |
| Income tax | — | -$24M | -$765,000 | — | -$1M | -$227,000 | — | $0 | $0 | $0 |
| Net income | -$129M | -$93M | -$151M | -$51M | -$60M | -$71M | -$112M | -$141M | -$158M | -$259M |
| EPS (diluted) | -$18.99 | -$10.86 | -$14.48 | -$3.51 | -$2.02 | -$1.64 | -$2.40 | -$2.92 | -$2.45 | -$3.90 |
| Diluted shares | 7M | 9M | 10M | 15M | 30M | 43M | 47M | 48M | 64M | 66M |
| Operating margin | -1958.7% | -953.7% | -1640.1% | -1540.2% | -854.1% | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -18599.8% |
| Net margin | -1894.0% | -730.1% | -1585.1% | -1424.0% | -805.9% | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -16748.0% |
Balance sheet
Fiscal years, from Celldex Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $190M | $139M | $94M | $64M | $194M | $408M | $305M | $424M | $725M | $519M |
| Total current assets | $196M | $145M | $99M | $67M | $198M | $411M | $318M | $432M | $747M | $535M |
| Property, plant and equipment | $13M | $10M | $6M | $4M | $4M | $4M | $4M | $4M | $4M | $5M |
| Goodwill | $91M | $91M | — | — | — | — | — | — | — | — |
| Total assets | $383M | $316M | $156M | $123M | $236M | $445M | $353M | $466M | $792M | $583M |
| Total current liabilities | $35M | $28M | $13M | $12M | $14M | $17M | $19M | $31M | $40M | $51M |
| Total liabilities | $118M | $79M | $32M | $29M | $26M | $25M | $27M | $36M | $45M | $56M |
| Shareholders' equity | $265M | $236M | $124M | $94M | $209M | $419M | $326M | $429M | $747M | $527M |
| Net debt | -$42M | -$40M | -$24M | -$11M | -$44M | -$39M | -$29M | -$35M | -$28M | -$29M |
Cash flow
Fiscal years, from Celldex Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$113M | -$100M | -$75M | -$46M | -$40M | -$61M | -$104M | -$107M | -$158M | -$211M |
| Capital spending | $3M | $2M | $813,000 | $731,000 | $2M | $1M | $2M | $2M | $2M | $3M |
| Free cash flow | -$116M | -$102M | -$76M | -$47M | -$42M | -$62M | -$106M | -$109M | -$160M | -$214M |
| Stock-based compensation | $15M | $12M | $8M | $5M | $4M | $9M | $16M | $24M | $34M | $36M |
| Net borrowing | — | — | — | — | $0 | — | — | — | — | — |
| Free cash flow margin | -1706.3% | -798.2% | -797.3% | -1319.5% | -565.6% | -1336.4% | -4478.6% | -1585.2% | -2274.9% | -13829.1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CLDX.
Open CLDX in InvestinglyQuestions
What was Celldex Therapeutics's revenue in 2025?
$2M in fiscal 2025, from its 10-K filing.
How much free cash flow does Celldex Therapeutics generate?
-$214M in fiscal 2025 (operating cash flow minus capital spending).
From Celldex Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.